Non Small Cell Lung Cancer Clinical Trial
Official title:
Distributed Learning of a Survival Model in More Than 20.000 Lung Cancer Patients
Machine learn a predictive model from more than 20.000 non-small cell lung cancer patients from more than 5 health care providers from more than 5 countries.
All current innovations in medicine, including personalized medicine; artificial
intelligence; (Big) data driven medicine; learning health care system; value based health
care and decision support systems, rely on the sharing of data across health care providers.
But sharing of data is hampered by administrative, political, ethical and technical
barriers(Sullivan et al., 2011). This limits the amount of health data available for the
above innovations and life sciences in general as well as other secondary uses such as
quality improvement.
The investigators hypothesize that sharing questions rather than sharing data is a better
approach and can unlock orders of magnitude more data while limiting privacy and other
concerns. An infrastructure to bring questions to the data has been demonstrated to work
recently in project such as euroCAT(Lambin et al., 2013; Deist et al., 2017), Datashield
(Gaye et al., 2014) and OHDSI (Hripcsak et al., 2015). However, the scale of the prior work
has been limited in terms of the number of data subjects, number of data providers and global
coverage.
In the experience of the investigators, the main challenges of scaling up the infrastructure
are 1) the effort necessary to make data FAIR at each site ("stations"), 2) the technical and
legal governance ("track") and 3) the mathematics and engineering of learning applications
("trains") - together called the Personal Health Train (PHT) infrastructure. Since multiple
years a global consortium of healthcare providers, scientists and commercial parties called
CORAL (Community in Oncology for RApid Learning) have worked on all three PHT challenges.
The aim of this study is to show that the PHT distributed learning infrastructure can be
scaled to many 1000s of patients, specifically the investigators aim to machine learn a
predictive model from more than 20.000 non-small cell lung cancer patients from more than 5
health care providers from more than 5 countries.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |